Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (191-200 of 361) with videos related to

Pageof 37
Sort By:
Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2022
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate CancerEric Feng, Nicholas R Rydzewski, Meng Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate CancerEric J Small, Raymond S Lance, Thomas A Gardner, et al.
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic responseCharles J Ryan, Shreya Shah, Eleni Efstathiou, et al.
Future Oncology (London, England)|August 20, 2024
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studiesLawrence I Karsh, Katherine B Bevans, Fred Saad, et al.
JCO Oncology Practice|December 21, 2021
Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate CancerDaniel H Kwon, Sneha Karthikeyan, Alison Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancerEric J Small, Natalie Sacks, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2020
Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate CancerCarlos Perez-Ruixo, Oliver Ackaert, Daniele Ouellet, et al.
Pageof 37

Showing results (191-200 of 361) with videos related to

Sort By:
Pageof 37
Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2022
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate CancerEric Feng, Nicholas R Rydzewski, Meng Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate CancerEric J Small, Raymond S Lance, Thomas A Gardner, et al.
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic responseCharles J Ryan, Shreya Shah, Eleni Efstathiou, et al.
Future Oncology (London, England)|August 20, 2024
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studiesLawrence I Karsh, Katherine B Bevans, Fred Saad, et al.
JCO Oncology Practice|December 21, 2021
Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate CancerDaniel H Kwon, Sneha Karthikeyan, Alison Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancerEric J Small, Natalie Sacks, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2020
Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate CancerCarlos Perez-Ruixo, Oliver Ackaert, Daniele Ouellet, et al.
Pageof 37